The development of efficacious and safe post transcriptional gene silencing (PTGS) agents is a challenging scientific endeavor that embraces "biocomplexity" at many levels. The target mRNA exhibits a level of structural complexity that profoundly limits annealing of PTGS agents. PTGS agents are macromolecular RNAs that must be designed to fold into catalytically active structures able to cleave the target mRNA. Pushing into and beyond the biological complexity requires new technologies for high throughput screening to efficiently and rapidly assess a set of biological and experimental variables engaged in RNA drug discovery. © 2012 Springer Science+Business Media, LLC.
CITATION STYLE
Sullivan, J. M., Yau, E. H., Taggart, R. T., Butler, M. C., & Kolniak, T. A. (2012). Relieving bottlenecks in RNA drug discovery for retinal diseases. In Advances in Experimental Medicine and Biology (Vol. 723, pp. 145–153). https://doi.org/10.1007/978-1-4614-0631-0_20
Mendeley helps you to discover research relevant for your work.